drugset / Trial / NCT07614022
A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)
Phase 1
Not yet recruiting
26 enrolled
Wake Forest University Health Sciences
Atrium Health Wake Forest Baptist · collabNational Cancer Institute (NCI) · collabNewave Pharmaceutical Inc · collab
NaSequentialOpen-labelTreatment
Summary
The purpose of this research study is to see if a drug called LP-118 is safe and effective for treating adults with Philadelphia chromosome-positive (Ph+) B cell acute lymphoblastic leukemia (ALL), when given with ponatinib, dexamethasone, methotrexate and blinatumomab (the standard treatment for this type of cancer).
Timeline
- Start
- 2026-10
- Primary completion
- 2030-03
- Completion
- 2030-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LP-118 | Small molecule | 10 mg | Oral |
| Subject | LP-118 | Small molecule | 50 mg | Oral |
| Subject | LP-118 | Small molecule | 100 mg | Oral |
| Subject | LP-118 | Small molecule | 200 mg | Oral |
| Subject | LP-118 | Small molecule | 300 mg | Oral |